[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625471":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":35,"locations":41,"responsibleParty":82,"collaborators":85,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":92,"sex":98,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":11,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":43,"whyStopped":11,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"University of Primorska","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Open CGM","EXPERIMENTAL",null,[13],"Device: Continuous Glucose Monitoring (CGM)",{"label":15,"type":10,"description":11,"interventionNames":16},"Blinded CGM",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DEVICE","Continuous Glucose Monitoring (CGM)","Use of a continuous glucose monitoring system to measure interstitial glucose levels. During the open CGM phase, participants have real-time access to glucose data; during the blinded CGM phase, glucose data are masked from participants.",[15,9],[24,28,32],{"name":25,"affiliation":26,"role":27},"Ajda Urbas, MD","Diabetes Outpatient Clinic, Community Health Center Koper, Slovenia","PRINCIPAL_INVESTIGATOR",{"name":29,"affiliation":30,"role":31},"Mojca Jensterle Sever, PhD","University Medical Centre Ljubljana, Department Of endocrinology and diabetes, Medical Faculty, University of Ljubljana","STUDY_CHAIR",{"name":33,"affiliation":34,"role":31},"Zala Jenko Pražnikar, PhD","University of Primorska, Faculty of Health Sciences",[36],{"name":37,"role":38,"phone":39,"phoneExt":11,"email":40},"Ajda Urbas, medical doctor","CONTACT","0038631626966","ajda.urbas@gmail.com",[42,59,70],{"facility":34,"status":43,"city":44,"state":11,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Izola","6310","Slovenia","SI",{"type":49,"coordinates":50},"Point",[51,52],13.66015,45.53661,{"lat":52,"lon":51},[55,57],{"name":33,"role":38,"phone":11,"phoneExt":11,"email":56},"zala.praznikar@upr.si",{"name":58,"role":38,"phone":11,"phoneExt":11,"email":11},"Ana Petelin, PhD",{"facility":26,"status":43,"city":60,"state":11,"zip":61,"country":46,"countryCode":47,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Koper","6000",{"type":49,"coordinates":63},[64,65],13.72963,45.5482,{"lat":65,"lon":64},[68],{"name":25,"role":38,"phone":11,"phoneExt":11,"email":69},"ajda.pipan@gmail.com",{"facility":71,"status":43,"city":72,"state":11,"zip":73,"country":46,"countryCode":47,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Department Of endocrinology and diabetes, Medical Faculty, University of Ljubljana","Ljubljana","1000",{"type":49,"coordinates":75},[76,77],14.50513,46.05108,{"lat":77,"lon":76},[80],{"name":29,"role":38,"phone":11,"phoneExt":11,"email":81},"mojcajensterle@yahoo.com",{"type":27,"investigatorFullName":83,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Zala Jenko Praznikar","Assoc. Prof.",[86,88],{"name":26,"class":87},"UNKNOWN",{"name":89,"class":6},"University Medical Centre Ljubljana","100625471","the-impact-of-continuous-glucose-monitoring-on-glucose-variability-and-weight-loss-in-individuals-with-prediabetes-and-obesity-100625471",false,"NCT07423065","The Impact of Continuous Glucose Monitoring on Glucose Variability and Weight Loss in Individuals With Prediabetes and Obesity","The Impact of Continuous Glucose Monitoring on Behavioral Change, Glucose Variability and Weight Loss in Individuals With Prediabetes and Obesity - a Randomized Crossover Study","CGM","Inclusion Criteria:\n\n* Adults aged 18-70 years.\n* BMI ≥ 27 kg\u002Fm² (overweight or obese).\n* Prediabetes, confirmed by:\n\nImpaired fasting glucose (IFG: 5.6-6.9 mmol\u002FL), and\u002For Impaired glucose tolerance (IGT: 2-hour OGTT glucose 7.8-11.0 mmol\u002FL).\n\n* Stable body weight (±3 kg) in the last 3 months.\n* No current use of antidiabetic or weight-loss medications.\n* Willingness and ability to wear a CGM device as instructed.\n* Capacity to provide written informed consent.\n* Recruitment from the Diabetes Outpatient Clinic, Community Health Center Koper (identified and invited from the clinic's database).\n\nExclusion Criteria:\n\n* Diagnosis of type 1 or type 2 diabetes mellitus (fasting glucose ≥ 7.0 mmol\u002FL or HbA1c ≥ 6.5%).\n* Current or recent (within 3 months) use of:\n* Any antidiabetic medication (insulin, metformin, GLP-1RA, SGLT2i, etc.), or anti-obesity pharmacotherapy.\n* Pregnancy, breastfeeding, or planned pregnancy during the study period.\n* Severe chronic disease that could influence glucose metabolism or study participation (e.g., chronic liver disease, renal failure, active malignancy).\n* Endocrine disorders affecting metabolism (e.g., untreated thyroid disease, Cushing's syndrome).\n* Severe psychiatric illness or cognitive impairment limiting adherence or comprehension.\n* Use of medications known to affect glucose metabolism (e.g., corticosteroids, atypical antipsychotics).\n* Implanted electronic medical devices (e.g., pacemaker, defibrillator) that may interfere with CGM function.\n* Known allergy or skin reaction to CGM adhesives or device materials.\n* Participation in another interventional study within the previous 3 months.","ALL","18 Years","70 Years",{"count":102,"type":103},34,"ESTIMATED","INTERVENTIONAL",[106],"NA","This randomized, crossover interventional study evaluates the effects of real-time (open) versus blinded continuous glucose monitoring (CGM) on glycemic variability, lifestyle behaviors, and metabolic outcomes in adults with prediabetes and overweight or obesity (BMI ≥ 27 kg\u002Fm²). Thirty participants will undergo both open and blinded CGM phases, separated by a washout period. The study aims to assess whether access to real-time glucose data promotes behavioral change and improves metabolic health compared with blinded CGM use.",[109,110],"Pre Diabetic","Obesity & Overweight",[112,113,114,115],"continuous glucose monitoring","obesity","prediabetes","behavior","2026-04-27",{"date":118,"type":119},"2026-04-28","ACTUAL",{"date":121,"type":103},"2026-09-01",{"date":123,"type":103},"2027-09-01",{"name":5,"class":6},3]